Cilj: Ispitati dozimetrijske trendove na organe od rizika i akutnu toksičnost u pacijenata s karcinomom pluća nemalih stanica liječenih trodimenzionalnom konformalnom kemoradioterapijom u jednom onkološkom centru. Metode: Ovo je retrospektivna studija provedena na Klinici za onkologiju i radioterapiju KBC-a Split. Prikupljeni su podatci oboljelih od lokalno uznapredovalog nesitnostaničnog karcinoma pluća liječenih trodimenzionalnom konformalnom radioterapijom od 2011. godine do početka 2019. godine. Prikupljeni su podatci pacijenata koji su se zračili primarno, adjuvantno i/ili neoadjuvantno. Uključeni pacijenti primili su najmanje jedan ciklus kemoterapije. Ciljni volumeni i organi od rizika ocrtani su prema radioterapijskim smjernicama. Rezultati: Medijan doze na “planing treatment volume” bio je 56 Gy. Najčešća akutna radijacijska toksičnost bila je akutni ezofagitis. Nije zabilježen nijedan slučaj akutnog radijacijskog pneumonitisa. Nije pokazana korelacija između prekoračenja doze na zadane volumene organa od rizika i toksičnosti istih, te smo ukazali na trend poboljšanja dozimetrijskih rezultata kroz godine liječenja. Zaključak: Toksičnost liječenja 3D KRT-om lokalno uznapredovalog raka pluća u Klinici za onkologiju i radioterapiju KBC-a Split usporediva je s objavljenim rezultatima drugih svjetskih institucija. S duljim vremenom primjene trodimenzionalne konformalne radioterapije u kliničkoj praksi postiže se optimalna raspodjela doza zračenja na rizične organe. AIM OF THE STUDY: To investigate organs-at-risk toxicity with concomitant chemo radiotherapy in non-small cell lung cancer patients, and to explore dosimetry trends for organs-at-risk over the years. To investigate the rates of acute toxicities and to compare the results with the worldwide literature. SUBJECTS AND METHODS: This is a retrospective study conducted at the Department of Oncology and Radiotherapy at University Hospital of Split. Data were collected from patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal chemo radiotherapy from 2011 to early 2019. Data were collected from patients who were treated with primary, adjuvant, and/or neoadjuvant radiotherapy. The patients received at least one cycle of chemotherapy. The target volumes and organs of risk were delineated according to radiotherapy guidelines. RESULTS: The median dose on planning treatment volume was 56 Gy. The most common acute radiation toxicity was radiation esophagitis. No cases of acute radiation pneumonitis were noted. No correlation has been noted between dose override on organs-at-risk volumes and toxicity, and we have shown a trend of improved dosimetry results through the years. CONCLUSION: The toxicity of treatment with 3D conformal radiotherapy for locally advanced lung cancer at the Department of Oncology and Radiotherapy at University Hospital of Split is comparable to the published results of other worldwide institutions. With longer use of 3D conformal radiotherapy we have seen improved dosimetry results over the years.